Xenia M. Hart

Keio University — Japan

Medicine · Health Sciences

12h-index352citations51works3.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Treatment of Major Depression(25), Schizophrenia research and treatment(21), Electroconvulsive Therapy Studies(10), Pharmaceutical studies and practices(8), Neurotransmitter Receptor Influence on Behavior(7)

Publications51 total

Serum concentrations of selective serotonin reuptake inhibitors and atypical antipsychotics in children and adolescents: data from routine clinical care
Journal of Neural Transmission·2025Open Access
The sense and nonsense of antipsychotic combinations: A model for dopamine D2/3 receptor occupancy
Translational Psychiatry·2025Open Access
How to Determine a Therapeutic Reference Range for a Psychotropic Drug Systematically? Recommendations of the TDM Task Force of the AGNP
Therapeutic Drug Monitoring·2025· 4 citedOpen Access
Wie entstehen therapeutische Referenzbereiche für Psychopharmaka?
Psychopharmakotherapie·2025
Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics
The World Journal of Biological Psychiatry·2024· 26 citedOpen Access
Mirtazapine blood levels and antidepressant response
International Journal of Psychiatry in Clinical Practice·2024· 2 cited
Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments
Pharmacopsychiatry·2024· 7 citedOpen Access
Therapeutic reference range for duloxetine in the treatment of depression revised: a systematic review and meta-analysis
Pharmacopsychiatry·2024· 1 cited
Therapeutic Drug Monitoring of Antipsychotics: Innovations in the 2024 Consensus Guidelines
Pharmacopsychiatry·2024
Elevation of alpha-1 acid glycoprotein during acute infection increases clozapine levels without signs of intoxication
Pharmacopsychiatry·2024
PET-derived modelling of D2-receptor occupancy of antipsychotic polypharmacy in patients with schizophrenia
Pharmacopsychiatry·2024
Update on dose-related reference ranges for psychotropic drugs
Pharmacopsychiatry·2024
Unraveling the Influence of Age, IQ, Education, and Negative Symptoms on Neurocognitive Performance in Schizophrenia: A Conditional Inference Tree Analysis
Pharmacopsychiatry·2024· 5 citedOpen Access
Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antidepressants
Therapeutic Drug Monitoring·2024· 6 cited
Neurovascular coupling of striatal dopamine D2/3 receptor availability and perfusion using simultaneous PET/MR in humans
Neuroscience Applied·2024· 2 citedOpen Access
Therapeutic reference range for duloxetine in the treatment of depression revised: A systematic review and meta-analysis
Neuroscience Applied·2024· 7 citedOpen Access
Neurovascular coupling of D2/D3 dopamine receptors using simultaneous PET/MR in humans
Neuroscience Applied·2024Open Access
Antipsychotic polypharmacy for schizophrenia from a positron emission tomography imaging perspective
Neuroscience Applied·2024Open Access
Mirtazapine blood levels and antidepressant response
Neuroscience Applied·2024Open Access
Elevation of Alpha-1 Acid Glycoprotein During Acute Infection Increases Clozapine Levels Without Signs of Intoxication
Journal of Clinical Psychopharmacology·2023· 2 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Gerhard Gründer(34), Christoph Hiemke(20), Georgios Schoretsanitis(18), Gerald Zernig(14), Andreas Conca(13), Ursula Havemann‐Reinecke(13), Moritz Spangemacher(10), Luzie Eichentopf(9), Xenija Lense(9), Vincenzo De Florio(9), Thomas Riemer(9), Gudrun Hefner(7), Michael Paulzen(5), Alessandro Serretti(5), Friederike Amann(5), Hiroyuki Uchida(5), M. I. Kuzin(4), Werner Steimer(4), Frank Faltraco(4), Christian N. Schmitz(4)